Fulcrum Therapeutics shares are trading lower after the company announced the discontinuation of its pociredir program and the initiation of a comprehensive review of strategic alternatives. Also, HC Wainwright downgraded the stock from Buy to Neutral and cut its price target from $25 to $3.